Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serna, D. S.
Right arrow Articles by Loberiza, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serna, D. S.
Right arrow Articles by Loberiza, F. R., Jr
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 20 (October), 2003: 3754-3760
© 2003 American Society for Clinical Oncology

Trends in Survival Rates After Allogeneic Hematopoietic Stem-Cell Transplantation for Acute and Chronic Leukemia by Ethnicity in the United States and Canada

Derek S. Serna, Stephanie J. Lee, Mei-jie Zhang, K. Scott Baker, Mary Eapen, Mary M. Horowitz, John P. Klein, J. Douglas Rizzo, Fausto R. Loberiza, Jr

From the International Bone Marrow Transplant Registry, Division of Biostatistics, Health Policy Institute, and Division of Neoplastic Diseases and Related Disorders, Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI; Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, MA; and Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN.

Address reprint requests to Fausto R. Loberiza Jr, MD, MS, International Bone Marrow Transplant Registry, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226; e-mail: faustol{at}mcw.edu.

Purpose: Differences in survival among ethnic groups in the United States are reported in numerous diseases and treatment strategies. Whether survival after allogeneic hematopoietic stem-cell transplantation (HSCT) differs by ethnicity is uncertain.

Patients and Methods: Patients (n = 6,443) receiving HLA-identical sibling HSCT for acute or chronic leukemia in the United States or Canada between 1985 and 1999 and reported to the International Bone Marrow Transplant Registry were included. The survival of recipients reported as white, black, Hispanic, or Asian was compared using Cox proportional hazards regression adjusting for other clinical factors. Three 5-year periods were studied to evaluate changes over time.

Results: Hispanics compared with whites had lower 1-year (53% v 65%; P < .001) and 3-year adjusted survival rates (38% v 53%; P < .001) between 1995 and 1999, the most recent period studied. We failed to find significant differences in survival rates comparing whites with blacks or with Asians in any of the time periods. Overall survival for the entire cohort improved over time, from 56% to 63% at 1 year and from 43% to 51% at 3 years, with greater improvements noted among blacks (45% to 61% at 1 year and 34% to 48% at 3 years).

Conclusion: Disparities remain in survival rates between whites and Hispanics despite adjustment for clinical factors. Factors not accounted for in this analysis, such as comorbid disease, socioeconomic status, healthcare access and delivery, and psychosocial and cultural variables, require further prospective study.

Presented orally during the 44th American Society of Hematology Annual Meeting in Philadelphia, PA, December 6–10, 2002.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Clin TrialsHome page
B. Logan, E. Leifer, C. Bredeson, M. Horowitz, M. Ewell, S. Carter, and N. Geller
Use of biological assignment in hematopoietic stem cell transplantation clinical trials
Clinical Trials, December 1, 2008; 5(6): 607 - 616.
[Abstract] [PDF]


Home page
haematolHome page
D. Pulte, A. Gondos, and H. Brenner
Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century
Haematologica, April 1, 2008; 93(4): 594 - 600.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. S. Baker, F. R. Loberiza Jr, H. Yu, M. S. Cairo, B. J. Bolwell, W. A. Bujan-Boza, B. M. Camitta, J. J. Garcia, W. G. Ho, J. L. Liesveld, et al.
Outcome of Ethnic Minorities With Acute or Chronic Leukemia Treated With Hematopoietic Stem-Cell Transplantation in the United States
J. Clin. Oncol., October 1, 2005; 23(28): 7032 - 7042.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Boeckh and W. G. Nichols
The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
Blood, March 15, 2004; 103(6): 2003 - 2008.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online